A retrospective study analysing the impact of PD-1 inhibitors on thyroid-related adverse events and identifying TKI as a major risk factor for the development of hypothyroidism
Latest Information Update: 12 Apr 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 12 Apr 2021 New trial record